WAY vs UNH vs CVS vs CI vs ELV vs JPM

For growth investors, Waystar Holding Corp.

(WAY) is the stronger pick with 16. 5% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Cigna Corporation (CI) offers the better valuation at 13. 4x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cigna Corporation (CI) is the cheapest at 13.

4x versus CVS Health Corporation at 73. 4x. On forward P/E, Cigna Corporation is actually cheaper at 9. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Elevance Health Inc. 's 2. 18x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -9. 4% for Waystar Holding Corp. (WAY). Over 10 years, the gap is even starker: JPM returned +465. 8% versus WAY's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

19β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 394% more volatile than CVS relative to the S&P 500. On balance sheet safety, Waystar Holding Corp. (WAY) carries a lower debt/equity ratio of 39% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Waystar Holding Corp.

(WAY) is pulling ahead at 16. 5% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, WAY leads at 16. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 2. 6% for CVS. At the gross margin level — before operating expenses — WAY leads at 64. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Elevance Health Inc. 's 2. 18x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Cigna Corporation (CI) trades at 9. 8x forward P/E versus 22. 2x for UnitedHealth Group Incorporated — 12. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.

In this comparison, CVS (2.

6% yield), UNH (2. 1% yield), CI (2. 0% yield), JPM (1. 9% yield), ELV (1. 7% yield) pay a dividend. WAY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 2. 6% yield). Both have compounded well over 10 years (CVS: +29. 5%, WAY: -9. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WAY (Technology) and UNH (Healthcare) and CVS (Healthcare) and CI (Healthcare) and ELV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WAY is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap quality compounder stock; CI is a mid-cap deep-value stock; ELV is a mid-cap deep-value stock; JPM is a large-cap deep-value stock. UNH, CVS, CI, ELV, JPM pay a dividend while WAY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.